{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:11:49Z","timestamp":1789578709143,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Zopiclone, a cyclopyrrolone derivative, is commonly employed for the short-term treatment of different types of insomnia. In comparison to benzodiazepines, Zopiclone appears to have a lower risk of abuse potential and withdrawal symptoms. Nevertheless, as the use of Zopiclone has increased, reports of abuse and dependence have begun to surface in the literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>This case report describes a 43-year-old male patient who has been taking zopiclone for 12 years, with a maximum daily dose of 112.5 mg. Two days after discontinuing the medication, the patient experienced withdrawal symptoms such as palpitations, sweating, irritability, hallucinations, and impulsive behavior, which resulted in his admission to a psychiatric hospital. After 17 days of treatment with diazepam, quetiapine fumarate, magnesium valproate, and trazodone hydrochloride, the patient\u2019s withdrawal symptoms alleviated, sleep quality improved, and medication cravings decreased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Similar to benzodiazepines, Zopiclone may also result in abuse and dependency issues. Therefore, when prescribing Zopiclone, physicians must be fully aware of it.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1592065","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T16:19:54Z","timestamp":1748017194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Dependence on zopiclone: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Nana","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med Clinics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12788\/jfp","article-title":"Insomnia management: A review and update","volume":"72","author":"Shaha","year":"2023","journal-title":"J Family Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326040-00004","article-title":"New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon","volume":"26","author":"Terzano","year":"2003","journal-title":"Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106927","article-title":"Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics","volume":"24","author":"Nutt","year":"2009","journal-title":"J Psychopharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00023210-200519010-00008","article-title":"Zolpidem: a review of its use in the management of insomnia","volume":"19","author":"Swainston Harrison","year":"2005","journal-title":"CNS Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0292-0","article-title":"The clinical and forensic toxicology of Z-drugs","volume":"9","author":"Gunja","year":"2013","journal-title":"J Med Toxicol"},{"key":"B8","article-title":"GPs\u2019 attitudes to benzodiazepine and \u2018Z-drug\u2019 prescribing: a barrier to implementation of evidence and guidance on hypnotics","volume":"56","author":"Siriwardena","year":"2006","journal-title":"Br J Gen practice : J R Coll Gen Practitioners"},{"key":"B9","doi-asserted-by":"publisher","first-page":"zsad124","DOI":"10.1093\/sleep\/zsad124","article-title":"Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018: a sales data analysis","volume":"46","author":"Ma","year":"2023","journal-title":"Sleep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177645","article-title":"Inpatient Z-drug use commonly exceeds safe dosing recommendations","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/pds.2630020413","article-title":"PEM report number 10. Zopiclone","volume":"2","author":"Inman","year":"1993","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00491.x","article-title":"Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data","volume":"98","author":"Hajak","year":"2003","journal-title":"Addiction"},{"key":"B14","article-title":"Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena","author":"Bianchi","year":"1990","journal-title":"Int Clin Psychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agg123","article-title":"DEPENDENCE ON LEGAL PSYCHOTROPIC DRUGS AMONG ALCOHOLICS","volume":"38","author":"Johansson","year":"2003","journal-title":"Alcohol Alcoholism"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470100417","article-title":"Zopiclone abuse in South Wales: Three case reports","volume":"10","author":"Sullivan","year":"1995","journal-title":"Hum Psychopharmacology: Clin Exp"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/09595230601052777","article-title":"Zopiclone misuse: an update from Dublin","volume":"26","author":"Bannan","year":"2007","journal-title":"Drug Alcohol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-4-403","article-title":"Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: a case report","volume":"4","author":"Morinan","year":"2010","journal-title":"J Med Case Rep"},{"key":"B19","article-title":"Retrospective Study on Characteristics of 104 Zopiclone Abusers in a Substance Abuse Clinic in Hong Kong","author":"Ming","year":"2006"},{"key":"B20","article-title":"Structure, pharmacology, and function of GABAA receptor subtypes","volume-title":"Advances in pharmacology","author":"Sieghart","year":"2006"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00442-5","article-title":"GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain","volume":"101","author":"Pirker","year":"2000","journal-title":"Neuroscience"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103017001723","article-title":"Zolpidem dependence case series: possible neurobiological mechanisms and clinical management","volume":"17","author":"Liappas","year":"2003","journal-title":"J Psychopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(92)90164-S","article-title":"Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone","volume":"29","author":"Byrnes","year":"1992","journal-title":"Brain Res Bull"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.002792","article-title":"Cell surface expression of homomeric GABAA receptors depends on single residues in subunit transmembrane domains","volume":"293","author":"Hannan","year":"2018","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7125.117","article-title":"Physical dependence on zopiclone: case reports","volume":"316","author":"Jones","year":"1998","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/bf03160567","article-title":"Zopiclone: is there any dependence and abuse potential","volume":"244","author":"Lader","year":"1997","journal-title":"J Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afi132","article-title":"Zopiclone withdrawal: an unusual cause of delirium in the elderly","volume":"34","author":"Wong","year":"2005","journal-title":"Age Ageing"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.07.009","article-title":"Seizure following sudden zolpidem withdrawal","volume":"31","author":"Cuba\u0142a","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014457","article-title":"Misuse of zopiclone and convulsions during withdrawal","volume":"24","author":"Aranko","year":"1991","journal-title":"Pharmacopsychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.2018.18.issue-4","article-title":"Delirium associated with only one dose of zopiclone in an older adult","volume":"18","author":"Kalan","year":"2018","journal-title":"Psychogeriatrics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.64","article-title":"Expression of GABAA \u03b12-, \u03b21- and \u03f5-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder","volume":"3","author":"Fatemi","year":"2013","journal-title":"Trans Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1252397","article-title":"Severe chronic abuse of zolpidem for over 10 years: a case report and review of similar cases","volume":"14","author":"Moshfeghinia","year":"2023","journal-title":"Front Psychiatry"},{"key":"B33","unstructured":"Inclusion of zolpidem (INN) in Schedule IV of the Conven\n          \n          \n          \n          2001"},{"key":"B34","unstructured":"Advisory council on the misuse of drugs(ACMD)\n          \n          \n          \n          2013"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz007","article-title":"An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR). Regular research article","volume":"22","author":"Schifano","year":"2019","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1592065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T16:19:56Z","timestamp":1748017196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1592065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":35,"alternative-id":["10.3389\/fpsyt.2025.1592065"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1592065","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"1592065"}}